NASDAQ:VTVT - vTv Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $6.00
Forecasted Upside: 242.86 %
Number of Analysts: 1
Breakdown:
0 Sell Ratings
0 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$1.75 As of 09/23/2021 01:38 PM ET

▲ +0.05 (2.94%)

1 month | 3 months | 12 months

Get New vTv Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for VTVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VTVT

^$6.00

▲ +242.86% Upside Potential

This price target is based on 1 analysts offering 12 month price targets for vTv Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 242.86% upside from the last price of $1.75.

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in vTv Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/31/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/29/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/27/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/26/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/24/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/23/2021

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/22/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/24/2021	HC Wainwright	Reiterated Rating	Buy	$6.00	Medium
6/15/2020	Northland Securities	Initiated Coverage	Buy	$8.00	Medium
5/28/2020	Northland Securities	Initiated Coverage	Buy	$8.00	Low
3/18/2020	HC Wainwright	Reiterated Rating	Buy		High
2/10/2020	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $6.00	High
10/31/2019	Northland Securities	Reiterated Rating	Buy		Low
10/24/2019	Northland Securities	Reiterated Rating	Buy	$8.00	High
10/9/2019	Northland Securities	Set Price Target	Buy	$8.00	Low
9/18/2019	Northland Securities	Set Price Target	Buy	$8.00	Low
8/16/2019	HC Wainwright	Reiterated Rating	Buy	$5.00	High
8/1/2019	Northland Securities	Reiterated Rating	Buy	$8.00	High
6/28/2019	Northland Securities	Set Price Target	Buy	$8.00	Medium
6/7/2019	HC Wainwright	Reiterated Rating	Buy	$5.00	High
5/30/2019	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$5.00	High
5/6/2019	Northland Securities	Upgrade	Market Perform ➝ Outperform		Medium
3/18/2019	Northland Securities	Set Price Target	Hold	$3.00	High
2/27/2019	Northland Securities	Reiterated Rating	Hold	$3.00	Low
4/10/2018	Roth Capital	Downgrade	Buy ➝ Neutral	$18.00 ➝ $17.00	High
4/10/2018	Northland Securities	Downgrade	Outperform ➝ Market Perform	$28.00	High
4/10/2018	Seaport Global Securities	Downgrade	Buy ➝ Neutral		High
4/10/2018	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$4.00	High
4/10/2018	Stifel Nicolaus	Downgrade	Buy ➝ Hold		High
3/29/2018	Seaport Global Securities	Initiated Coverage	Buy	$14.00	High
3/8/2018	Roth Capital	Initiated Coverage	Buy ➝ Buy	$17.00	High
2/8/2018	Northland Securities	Initiated Coverage	Outperform ➝ Outperform	$28.00	Low
12/21/2017	Canaccord Genuity	Set Price Target	Buy	$15.00	Low
11/8/2017	Citigroup	Reiterated Rating	add		N/A
11/3/2017	Stifel Nicolaus	Reiterated Rating	Buy	$12.00	N/A
8/4/2017	Canaccord Genuity	Reiterated Rating	Buy	$15.00	Low
8/4/2017	HC Wainwright	Set Price Target	Buy	$13.00	Low
5/4/2017	HC Wainwright	Set Price Target	Buy	$13.00	Low
3/30/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$24.00	Low
3/30/2017	HC Wainwright	Reiterated Rating	Buy	$13.00	High
2/28/2017	HC Wainwright	Reiterated Rating	Buy	$13.00	N/A
2/28/2017	Canaccord Genuity	Reiterated Rating	Buy		N/A
12/18/2016	Canaccord Genuity	Set Price Target	Buy	$15.00	N/A
12/16/2016	HC Wainwright	Reiterated Rating	Buy	$13.00	N/A
12/15/2016	Stifel Nicolaus	Set Price Target	Buy	$14.00	N/A
11/8/2016	HC Wainwright	Reiterated Rating	Buy		N/A
10/15/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$24.00	N/A
9/26/2016	HC Wainwright	Initiated Coverage	Buy	$13.00	N/A

(Data available from 9/23/2016 forward)

News Sentiment Rating

1.06 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/25/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/27/2021

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/26/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/26/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/25/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/25/2021

1 very positive mentions
3 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

8/24/2021

1 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/23/2021

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

nasdaq.com
9/14/2021
Is vTv Therapeutics (NASDAQ:VTVT) In A Good Position To Invest In Growth?

Very Positive

finance.yahoo.com
9/13/2021
Multiple insiders bought vTv Therapeutics Inc. (NASDAQ:VTVT) stock earlier this year, a positive sign for shareholders

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Today's Range

Now: $1.75

$1.71

$1.75

50 Day Range

MA: $1.87

$1.68

$2.17

52 Week Range

Now: $1.75

$1.44

$4.75

Volume

4,947 shs

Average Volume

3,335,755 shs

Market Capitalization

$145.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of vTv Therapeutics?

The following Wall Street analysts have issued research reports on vTv Therapeutics in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for VTVT.

What is the current price target for vTv Therapeutics?

1 Wall Street analysts have set twelve-month price targets for vTv Therapeutics in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 242.9%. HC Wainwright has the highest price target set, predicting VTVT will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for vTv Therapeutics in the next year.
View the latest price targets for VTVT.

What is the current consensus analyst rating for vTv Therapeutics?

vTv Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VTVT will outperform the market and that investors should add to their positions of vTv Therapeutics.
View the latest ratings for VTVT.

What other companies compete with vTv Therapeutics?

Other companies that are similar to vTv Therapeutics include Chimerix, Greenwich LifeSciences, Chinook Therapeutics, Verastem, VistaGen Therapeutics, Inventiva, Summit Therapeutics, Epizyme, Vaccitech, Clovis Oncology, NRx Pharmaceuticals, Foghorn Therapeutics, Intercept Pharmaceuticals, Avadel Pharmaceuticals and PLx Pharma.

How do I contact vTv Therapeutics' investor relations team?

vTv Therapeutics' physical mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company's listed phone number is (336) 841-0300 and its investor relations email address is [email protected] The official website for vTv Therapeutics is www.vtvtherapeutics.com.